Alaunos Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Alaunos Therapeutics, Inc. (TCRT) reported Increase (Decrease) in Deferred Revenue of -$146.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-11-09
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was $0.00.
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was $0.00.
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$146.00K.
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$1.60M.
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2017 was -$6.39M.
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2016 was -$6.86M, a 112.84% decline from fiscal 2015.
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2015 was $53.42M.
- Alaunos Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2014 was -$1.37M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 94 month | Increase (Decrease) in Deferred Revenue 97 month | Increase (Decrease) in Deferred Revenue 100 month | Increase (Decrease) in Deferred Revenue 103 month | Increase (Decrease) in Deferred Revenue 106 month | Increase (Decrease) in Deferred Revenue 109 month | Increase (Decrease) in Deferred Revenue 112 month | Increase (Decrease) in Deferred Revenue 115 month | Increase (Decrease) in Deferred Revenue 118 month | Increase (Decrease) in Deferred Revenue 121 month | Increase (Decrease) in Deferred Revenue 124 month | Increase (Decrease) in Deferred Revenue 127 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | -$146.00K 10-Q · filed 2018-11-09 | -$1.74M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$146.00K 10-Q · filed 2018-08-08 | -$1.74M derived: sum of 3 quarters · filed 2018-08-08 | -$3.34M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||||||
| 2018-03-31 | -$146.00K 10-Q · filed 2018-05-10 | -$1.74M derived: sum of 2 quarters · filed 2018-05-10 | -$3.34M derived: sum of 3 quarters · filed 2018-11-09 | -$4.94M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||||||
| 2017-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$3.19M derived: sum of 2 quarters · filed 2018-11-09 | -$4.79M derived: sum of 3 quarters · filed 2018-11-09 | -$6.39M 10-K · filed 2018-03-01 | ||||||||||||
| 2017-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$3.19M derived: sum of 2 quarters · filed 2018-11-09 | -$4.79M 10-Q · filed 2018-11-09 | -$6.39M derived: sum of 4 quarters · filed 2018-11-09 | ||||||||||||
| 2017-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$3.19M 10-Q · filed 2018-08-08 | -$4.79M derived: sum of 3 quarters · filed 2018-08-08 | -$6.39M derived: sum of 4 quarters · filed 2018-08-08 | ||||||||||||
| 2017-03-31 | -$1.60M 10-Q · filed 2018-05-10 | -$3.19M derived: sum of 2 quarters · filed 2018-05-10 | -$4.79M derived: sum of 3 quarters · filed 2018-05-10 | -$6.49M derived: sum of 4 quarters · filed 2018-05-10 | ||||||||||||
| 2016-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$3.19M derived: sum of 2 quarters · filed 2018-03-01 | -$4.89M derived: sum of 3 quarters · filed 2018-03-01 | -$6.86M 10-K · filed 2018-03-01 | ||||||||||||
| 2016-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | -$3.29M derived: sum of 2 quarters · filed 2017-11-06 | -$5.26M 10-Q · filed 2017-11-06 | -$6.93M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2016-06-30 | -$1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-31 | -$3.67M 10-Q · filed 2017-07-31 | -$5.33M derived: sum of 3 quarters · filed 2018-03-01 | $50.30M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2016-03-31 | -$1.97M 10-Q · filed 2017-05-01 | -$3.64M derived: sum of 2 quarters · filed 2018-03-01 | $51.99M derived: sum of 3 quarters · filed 2018-03-01 | $51.72M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2015-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $53.96M derived: sum of 2 quarters · filed 2018-03-01 | $53.69M derived: sum of 3 quarters · filed 2018-03-01 | $53.42M 10-K · filed 2018-03-01 | ||||||||||||
| 2015-09-30 | $55.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $55.36M derived: sum of 2 quarters · filed 2016-11-09 | $55.09M 10-Q · filed 2016-11-09 | $54.75M derived: sum of 4 quarters · filed 2017-02-16 | ||||||||||||
| 2015-06-30 | -$272.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$544.00K 10-Q · filed 2016-08-09 | -$884.00K derived: sum of 3 quarters · filed 2017-02-16 | -$1.52M derived: sum of 4 quarters · filed 2017-02-16 | ||||||||||||
| 2015-03-31 | -$272.00K 10-Q · filed 2016-05-10 | -$612.00K derived: sum of 2 quarters · filed 2017-02-16 | -$1.25M derived: sum of 3 quarters · filed 2017-02-16 | -$1.45M derived: sum of 4 quarters · filed 2017-02-16 | ||||||||||||
| 2014-12-31 | -$340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$973.00K derived: sum of 2 quarters · filed 2017-02-16 | -$1.17M derived: sum of 3 quarters · filed 2017-02-16 | -$1.37M 10-K · filed 2017-02-16 | ||||||||||||
| 2014-09-30 | -$633.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$833.00K derived: sum of 2 quarters · filed 2015-11-02 | -$1.03M 10-Q · filed 2015-11-02 | -$1.23M derived: sum of 4 quarters · filed 2016-02-24 | ||||||||||||
| 2014-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$400.00K 10-Q · filed 2015-08-10 | -$600.00K derived: sum of 3 quarters · filed 2016-02-24 | -$800.00K derived: sum of 4 quarters · filed 2016-02-24 | ||||||||||||
| 2014-03-31 | -$200.00K 10-Q · filed 2015-05-07 | -$400.00K derived: sum of 2 quarters · filed 2016-02-24 | -$600.00K derived: sum of 3 quarters · filed 2016-02-24 | -$800.00K derived: sum of 4 quarters · filed 2016-02-24 | $2.53M 10-Q · filed 2014-05-08 | |||||||||||
| 2013-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | -$400.00K derived: sum of 2 quarters · filed 2016-02-24 | -$600.00K derived: sum of 3 quarters · filed 2016-02-24 | -$800.00K 10-K · filed 2016-02-24 | $2.73M 10-K · filed 2014-03-03 | |||||||||||
| 2013-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | -$400.00K derived: sum of 2 quarters · filed 2014-10-30 | -$600.00K 10-Q · filed 2014-10-30 | -$800.00K derived: sum of 4 quarters · filed 2015-02-26 | $2.93M 10-Q · filed 2013-10-22 | |||||||||||
| 2013-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$400.00K 10-Q · filed 2014-08-07 | -$600.00K derived: sum of 3 quarters · filed 2015-02-26 | -$800.00K derived: sum of 4 quarters · filed 2015-02-26 | $3.13M 10-Q · filed 2013-08-08 | |||||||||||
| 2013-03-31 | -$200.00K 10-Q · filed 2014-05-08 | -$400.00K derived: sum of 2 quarters · filed 2015-02-26 | -$600.00K derived: sum of 3 quarters · filed 2015-02-26 | -$800.00K derived: sum of 4 quarters · filed 2015-02-26 | $3.33M 10-Q · filed 2013-05-07 | |||||||||||
| 2012-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$400.00K derived: sum of 2 quarters · filed 2015-02-26 | -$600.00K derived: sum of 3 quarters · filed 2015-02-26 | -$800.00K 10-K · filed 2015-02-26 | $3.53M 10-K · filed 2013-03-18 | |||||||||||
| 2012-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-22 | -$400.00K derived: sum of 2 quarters · filed 2013-10-22 | -$600.00K 10-Q · filed 2013-10-22 | -$800.00K derived: sum of 4 quarters · filed 2014-03-03 | $3.73M 10-Q · filed 2012-11-08 | |||||||||||
| 2012-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$400.00K 10-Q · filed 2013-08-08 | -$600.00K derived: sum of 3 quarters · filed 2014-03-03 | -$800.00K derived: sum of 4 quarters · filed 2014-03-03 | $3.93M 10-Q/A · filed 2012-08-28 | |||||||||||
| 2012-03-31 | -$200.00K 10-Q · filed 2013-05-07 | -$400.00K derived: sum of 2 quarters · filed 2014-03-03 | -$600.00K derived: sum of 3 quarters · filed 2014-03-03 | -$800.00K derived: sum of 4 quarters · filed 2014-03-03 | $4.13M 10-Q · filed 2012-05-03 | |||||||||||
| 2011-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$400.00K derived: sum of 2 quarters · filed 2014-03-03 | -$600.00K derived: sum of 3 quarters · filed 2014-03-03 | $4.33M 10-K · filed 2014-03-03 | $4.33M 10-K · filed 2012-02-29 | |||||||||||
| 2011-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-08 | -$400.00K derived: sum of 2 quarters · filed 2012-11-08 | $4.53M 10-Q · filed 2012-11-08 | $4.53M 10-Q · filed 2011-11-03 | ||||||||||||
| 2011-06-30 | -$200.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2012-08-28 | $4.73M 10-Q/A · filed 2012-08-28 | $4.73M 10-Q/A · filed 2011-08-09 | |||||||||||||
| 2011-03-31 | $4.93M 10-Q · filed 2012-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |